The purpose of this case series is to report the unexpected occurrence of four cases of late radiation-induced neurotoxicity with bevacizumab use following radiotherapy to the CNS. We retrospectively reviewed the case records of four patients, three with glioblastoma and one with bone metastases secondary to metastatic breast cancer, who were treated with radiotherapy and developed late radiation-induced neurotoxicity following bevacizumab use. Three cases of optic neuropathy in glioblastoma patients and a single case of Brown-Séquard syndrome in the thoracic spine of a patient with metastatic breast cancer are reported. We hypothesize that bevacizumab use following radiotherapy to the CNS may inhibit vascular endothelial growth factor-dependent repair of normal neural tissue, and thus may increase the risk of late radiation neurotoxicity. Phase III data on the safety and efficacy of bevacizumab use with radiation in the setting of glioblastoma is awaited.
This is a preview of subscription content, log in via an institution to check access.
References
Martel MK, Sandler HM, Cornblath WT et al (1997) Dose–volume complication analysis for visual pathway structures of patients with advanced paranasal sinus tumors. Int J Radiat Oncol Biol Phys 38:273–284
Bhandare N, Monroe AT, Morris CG et al (2005) Does altered fractionation influence the risk of radiation-induced optic neuropathy? Int J Radiat Oncol Biol Phys 62:1070–1077
Parsons JT, Bova FJ, Fitzgerald CR et al (1994) Radiation optic neuropathy after megavoltage external-beam irradiation: analysis of time–dose factors. Int J Radiat Oncol Biol Phys 30:755–763
Mayo C, Martel MK, Marks LB et al (2010) Radiation dose–volume effects of optic nerves and chiasm. Int J Radiat Oncol Biol Phys 76(Suppl):S28–S35
Rades D, Fehlauer F, Stalpers LJ et al (2004) A prospective evaluation of two radiotherapy schedules with 10 versus 20 fractions for the treatment of metastatic spinal cord compression: final results of a multicenter study. Cancer 101:2687–2692
Kirkpatrick JP, van der Kogel AJ, Schultheiss TE (2010) Radiation dose–volume effects in the spinal cord. Int J Radiat Oncol Biol Phys 76(Suppl):S42–S49
Kim KJ, Li B, Winer J et al (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841–844
Lee CG, Heijn M, di Tomaso E et al (2000) Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60:5565–5570
Hess C, Vuong V, Hegyi I et al (2001) Effect of VEGF receptor inhibitor PTK787/ZK222584 combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer 85:2010–2016
Li J, Huang S, Armstrong EA et al (2005) Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade. Int J Radiat Oncol Biol Phys 62:1477–1485
Narazaki M, Tosato G (2006) Ligand-induced internalization selects use of common receptor neuropilin-1 by VEGF165 and semaphorin3A. Blood 107:3892–3901
Zachary I (2005) Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential. Neurosignals 14:207–221
Sherman JH, Aregawi DG, Lai HM et al (2009) Optic neuropathy in patients with glioblastoma receiving bevacizumab. Neurology 73:1924–1926
Levin VA, Bidaut L, Hou P et al. (2010) Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys doi:10.1016/j.ijrobp.2009.12.061
Lai A, Filka E, McGibbon B et al (2008) Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 71:1372–1380
Lai A, Nghiemphu P, Green R et al. (2009) Phase II trial of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme [Abstract]. J Clin Oncol 27(Suppl): S15
Narayana A, Golfinos JG, Fischer I et al (2008) Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Radiat Oncol Biol Phys 72:383–389
Gutin PH, Iwamoto FM, Beal K et al (2009) Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75:156–163
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kelly, P.J., Dinkin, M.J., Drappatz, J. et al. Unexpected late radiation neurotoxicity following bevacizumab use: a case series. J Neurooncol 102, 485–490 (2011). https://doi.org/10.1007/s11060-010-0336-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-010-0336-0